Association of Tumor Infiltrating T-cell Density with Molecular Subtype, Racial Ancestry and Clinical Outcomes in Prostate Cancer

[1]  A. Chinnaiyan,et al.  Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. , 2018, The American journal of pathology.

[2]  J. Clohessy,et al.  Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms , 2018, Nature Medicine.

[3]  Faraz Hach,et al.  Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer , 2017, Clinical Cancer Research.

[4]  M. Loda,et al.  Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide , 2017, Clinical Cancer Research.

[5]  S. Gabriel,et al.  Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. , 2017, Cancer discovery.

[6]  P. Kantoff,et al.  Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Eshleman,et al.  MSH2 Loss in Primary Prostate Cancer , 2017, Clinical Cancer Research.

[8]  B. Trock,et al.  Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. , 2017, European urology.

[9]  K. Pienta,et al.  Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey–Holden Prostate Cancer Academy Meeting , 2017, The Prostate.

[10]  S. Dhanasekaran,et al.  Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. , 2016, Cell reports.

[11]  C. Drake,et al.  Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis , 2016, Prostate Cancer and Prostatic Diseases.

[12]  L. Diaz,et al.  Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. , 2016, The oncologist.

[13]  E. Klein,et al.  Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. , 2016, European urology.

[14]  P. Carroll,et al.  PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. , 2016, European urology focus.

[15]  J. Mefford,et al.  Mutational Landscape of Aggressive Prostate Tumors in African American Men. , 2016, Cancer research.

[16]  P. Nelson,et al.  Characterizing the molecular features of ERG‐positive tumors in primary and castration resistant prostate cancer , 2016, The Prostate.

[17]  James R. Eshleman,et al.  Microsatellite Instability as a Biomarker for PD-1 Blockade , 2016, Clinical Cancer Research.

[18]  Jennifer R. Rider,et al.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. , 2015, Journal of the National Cancer Institute.

[19]  J. Stanford,et al.  Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status , 2015, Prostate Cancer and Prostatic Disease.

[20]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[21]  Y. Nordby,et al.  Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure‐free survival in prostate cancer , 2014, The Prostate.

[22]  M. Rubin,et al.  Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men , 2014, Clinical Cancer Research.

[23]  S. Enkemann,et al.  Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. , 2013, The Journal of clinical investigation.

[24]  G. Sauter,et al.  High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. , 2013, European journal of cancer.

[25]  Aliccia Bollig-Fischer,et al.  Genes Associated with Prostate Cancer Are Differentially Expressed in African American and European American Men , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[26]  Jennifer R. Rider,et al.  CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3+ regulatory T cells with respect to lethal prostate cancer , 2013, Modern Pathology.

[27]  Laurin A. J. Mueller,et al.  Characterization of Transcriptional Changes in ERG Rearrangement-Positive Prostate Cancer Identifies the Regulation of Metabolic Sensors Such as Neuropeptide Y , 2013, PloS one.

[28]  G. Sauter,et al.  Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[29]  I. Mills,et al.  Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. , 2012, Neoplasia.

[30]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[31]  M. Rubin,et al.  TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients , 2011, The Prostate.

[32]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[33]  N. Palanisamy,et al.  Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. , 2011, Cancer research.

[34]  T. Dønnem,et al.  The prognostic value of intraepithelial and stromal CD3‐, CD117‐ and CD138‐positive cells in non‐small cell lung carcinoma , 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[35]  V. Vacic,et al.  Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival , 2009, Proceedings of the National Academy of Sciences.

[36]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[37]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[38]  Sean Yoder,et al.  Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study , 2009, Infectious Agents and Cancer.

[39]  O. Ludkovski,et al.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.

[40]  C. Busch,et al.  The prognostic impact of M‐CSF, CSF‐1 receptor, CD68 and CD3 in prostatic carcinoma , 2008, Histopathology.

[41]  Robyn L Prueitt,et al.  Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.

[42]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[43]  P. Lipponen,et al.  Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. , 2005, Anticancer research.

[44]  D. McMillan,et al.  The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer , 2004, British Journal of Cancer.

[45]  D. McMillan,et al.  The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer , 2003, British Journal of Cancer.

[46]  H Nagura,et al.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.

[47]  Y. Soini,et al.  Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma. , 1999, Lung cancer.

[48]  F. Saint,et al.  High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. , 1999, Urology.

[49]  J. Eastham,et al.  Clinical Characteristics and Biopsy Specimen Features in African-American and White Men Without Prostate Cancer , 1998 .

[50]  V. Kosma,et al.  Prognostic value of tumour‐infiltrating lymphocytes (TILs) in colorectal cancer , 1997, The Journal of pathology.

[51]  J. Jass,et al.  A NEW PROGNOSTIC CLASSIFICATION OF RECTAL CANCER , 1987, The Lancet.

[52]  W. Nelson,et al.  The inflammatory microenvironment and microbiome in prostate cancer development , 2018, Nature Reviews Urology.

[53]  T. Golabek,et al.  Prostate cancer with different ERG status may show different FOXP3-positive cell numbers. , 2016, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[54]  P. Lipponen,et al.  Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. , 1994, European journal of cancer.